Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
GHDX's Cash to Debt is ranked higher than
99% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. GHDX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GHDX' s Cash to Debt Range Over the Past 10 Years
Min: 4.9  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.74
GHDX's Equity to Asset is ranked higher than
70% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. GHDX: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
GHDX' s Equity to Asset Range Over the Past 10 Years
Min: -3.56  Med: 0.80 Max: 0.89
Current: 0.74
-3.56
0.89
Interest Coverage No Debt
GHDX's Interest Coverage is ranked higher than
97% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. GHDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GHDX' s Interest Coverage Range Over the Past 10 Years
Min: 80.08  Med: 10000.00 Max: 9999.99
Current: No Debt
80.08
9999.99
F-Score: 3
Z-Score: 12.06
M-Score: -3.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -13.12
GHDX's Operating margin (%) is ranked lower than
57% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. GHDX: -13.12 )
Ranked among companies with meaningful Operating margin (%) only.
GHDX' s Operating margin (%) Range Over the Past 10 Years
Min: -621.78  Med: -7.43 Max: 4.01
Current: -13.12
-621.78
4.01
Net-margin (%) -13.09
GHDX's Net-margin (%) is ranked lower than
57% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. GHDX: -13.09 )
Ranked among companies with meaningful Net-margin (%) only.
GHDX' s Net-margin (%) Range Over the Past 10 Years
Min: -602.86  Med: -7.61 Max: 3.81
Current: -13.09
-602.86
3.81
ROE (%) -25.28
GHDX's ROE (%) is ranked lower than
62% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. GHDX: -25.28 )
Ranked among companies with meaningful ROE (%) only.
GHDX' s ROE (%) Range Over the Past 10 Years
Min: -1865.06  Med: -15.45 Max: 7.79
Current: -25.28
-1865.06
7.79
ROA (%) -19.64
GHDX's ROA (%) is ranked lower than
62% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. GHDX: -19.64 )
Ranked among companies with meaningful ROA (%) only.
GHDX' s ROA (%) Range Over the Past 10 Years
Min: -53.45  Med: -12.16 Max: 6.18
Current: -19.64
-53.45
6.18
ROC (Joel Greenblatt) (%) -122.81
GHDX's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. GHDX: -122.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GHDX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1132.33  Med: -72.55 Max: 74.51
Current: -122.81
-1132.33
74.51
Revenue Growth (3Y)(%) 9.40
GHDX's Revenue Growth (3Y)(%) is ranked higher than
69% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. GHDX: 9.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GHDX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 19.70 Max: 136.8
Current: 9.4
0
136.8
» GHDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

GHDX Guru Trades in Q1 2015

Jim Simons 36,900 sh (+202.46%)
Chuck Royce 33,000 sh (unchged)
» More
Q2 2015

GHDX Guru Trades in Q2 2015

Jim Simons 267,200 sh (+624.12%)
Chuck Royce 33,000 sh (unchged)
» More
Q3 2015

GHDX Guru Trades in Q3 2015

Chuck Royce 35,000 sh (+6.06%)
Jim Simons 233,800 sh (-12.50%)
» More
Q4 2015

GHDX Guru Trades in Q4 2015

Chuck Royce 66,500 sh (+90.00%)
» More
» Details

Insider Trades

Latest Guru Trades with GHDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 119.05
GHDX's Forward P/E is ranked lower than
97% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.45 vs. GHDX: 119.05 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 6.55
GHDX's P/B is ranked lower than
89% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. GHDX: 6.55 )
Ranked among companies with meaningful P/B only.
GHDX' s P/B Range Over the Past 10 Years
Min: 3.3  Med: 7.21 Max: 14.31
Current: 6.55
3.3
14.31
P/S 3.04
GHDX's P/S is ranked lower than
67% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.13 vs. GHDX: 3.04 )
Ranked among companies with meaningful P/S only.
GHDX' s P/S Range Over the Past 10 Years
Min: 2.17  Med: 4.13 Max: 20.45
Current: 3.04
2.17
20.45
Current Ratio 3.26
GHDX's Current Ratio is ranked higher than
55% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. GHDX: 3.26 )
Ranked among companies with meaningful Current Ratio only.
GHDX' s Current Ratio Range Over the Past 10 Years
Min: 3.26  Med: 4.69 Max: 15.83
Current: 3.26
3.26
15.83
Quick Ratio 3.26
GHDX's Quick Ratio is ranked higher than
63% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. GHDX: 3.26 )
Ranked among companies with meaningful Quick Ratio only.
GHDX' s Quick Ratio Range Over the Past 10 Years
Min: 3.26  Med: 4.69 Max: 15.83
Current: 3.26
3.26
15.83
Days Sales Outstanding 43.77
GHDX's Days Sales Outstanding is ranked higher than
79% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. GHDX: 43.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
GHDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.03  Med: 29.20 Max: 46.22
Current: 43.77
22.03
46.22
Days Payable 39.26
GHDX's Days Payable is ranked lower than
66% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. GHDX: 39.26 )
Ranked among companies with meaningful Days Payable only.
GHDX' s Days Payable Range Over the Past 10 Years
Min: 14.62  Med: 46.44 Max: 92.94
Current: 39.26
14.62
92.94

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.70
GHDX's Price/Net Cash is ranked lower than
60% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.33 vs. GHDX: 16.70 )
Ranked among companies with meaningful Price/Net Cash only.
GHDX' s Price/Net Cash Range Over the Past 10 Years
Min: 3.64  Med: 12.16 Max: 22.82
Current: 16.7
3.64
22.82
Price/Net Current Asset Value 9.03
GHDX's Price/Net Current Asset Value is ranked lower than
52% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. GHDX: 9.03 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GHDX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.53  Med: 8.47 Max: 17
Current: 9.03
3.53
17
Price/Tangible Book 6.57
GHDX's Price/Tangible Book is ranked lower than
57% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.76 vs. GHDX: 6.57 )
Ranked among companies with meaningful Price/Tangible Book only.
GHDX' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.3  Med: 7.07 Max: 11.72
Current: 6.57
3.3
11.72
Price/Projected FCF 6.83
GHDX's Price/Projected FCF is ranked lower than
86% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.06 vs. GHDX: 6.83 )
Ranked among companies with meaningful Price/Projected FCF only.
GHDX' s Price/Projected FCF Range Over the Past 10 Years
Min: 4.17  Med: 5.36 Max: 38.47
Current: 6.83
4.17
38.47
Price/Median PS Value 0.74
GHDX's Price/Median PS Value is ranked higher than
66% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.96 vs. GHDX: 0.74 )
Ranked among companies with meaningful Price/Median PS Value only.
GHDX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.55  Med: 0.97 Max: 3.82
Current: 0.74
0.55
3.82
Earnings Yield (Greenblatt) (%) -4.83
GHDX's Earnings Yield (Greenblatt) (%) is ranked lower than
62% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. GHDX: -4.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GHDX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.83  Med: 0.90 Max: 1.3
Current: -4.83
-4.83
1.3

More Statistics

Revenue(Mil) $281
EPS $ -1.15
Beta0.75
Short Percentage of Float9.18%
52-Week Range $20.05 - 35.79
Shares Outstanding(Mil)32.54

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 289 331 371
EPS($) -0.78 -0.01 0.23
EPS without NRI($) -0.78 -0.01 0.23

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:G7H.Germany,
Genomic Health Inc was incorporated in Delaware in August 2000. It is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company is engaged in the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The Company's Oncotype DX breast and colon tests have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company provides its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ, or DCIS and a Genomic Prostate Score, or GPS, for prostate cancer. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, or RT-PCR, in standard tumor pathology specimens to provide tumor-specific information, or the "oncotype" of a tumor. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and its Oncotype DX colon cancer test analyzes the expression levels of 12 genes. Its Oncotype DX prostate cancer test measures the level of expression of 17 genes across four biological pathways to predict prostate cancer aggressiveness in men with low risk disease. It has a direct commercial presence with employees and consultants in the United States and certain other countries, and its Oncotype DX breast and colon cancer tests are also available outside of the United States through a network of distributors. The Company faces competition from companies that offer products or have conducted research to profile genes, gene expression or protein expression in breast, colon or prostate cancer, including public companies such as, GE Healthcare, a business unit of General Electric Company, Hologic, Inc., Myriad Genetics, Inc., NanoString Technologies, Inc., Novartis AG, Qiagen N.V. and Response Genetics, Inc., and many private companies. It faces competition from commercial laboratories with distribution networks for diagnostic tests, such as Laboratory Corporation of America Holdings and Quest Diagnostics Incorporated. The Company holds 32 issued patents in the United States and 65 issued patents outside of the United States. As a clinical reference laboratory, the Company is subject to hold certain federal, state and local licenses, certifications and permits to conduct its business.
» More Articles for NAS:GHDX

Headlines

Articles On GuruFocus.com
CEO of InVitae Corporation of Genomic Health Inc. Randal W. Scott Sold 30,000 Shares Jul 13 2012 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Mar 14 2011 
Genomic Health Inc. (GHDX) COO G Bradley Cole sells 2,500 Shares Mar 10 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Feb 14 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Jan 19 2011 

More From Other Websites
Genomic Health reports 4Q loss Feb 10 2016
Genomic Health reports 4Q loss Feb 10 2016
4:14 pm Genomic Health misses by $0.01, beats on revs; guides FY16 EPS below two analyst estimate,... Feb 10 2016
GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 10 2016
Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End... Feb 10 2016
Q4 2015 Genomic Health Inc Earnings Release - After Market Close Feb 10 2016
Genomic Health to Announce Fourth Quarter and Year-End 2015 Financial Results and Host Conference... Feb 03 2016
Genomic Health, Inc. – Value Analysis (NASDAQ:GHDX) : January 19, 2016 Jan 19 2016
Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : January 18, 2016 Jan 18 2016
Day 3 of #JPM16: Low-risk hookups vs. big-dollar tie-ups, seat gouging and the space race Jan 13 2016
Genomic Health Down on Bleak Preliminary Q4, '15 Results Jan 11 2016
Genomic Health Announces Plans to Launch Liquid Biopsy Mutation Panel in 2016 Jan 11 2016
Genomic Health downgraded by Piper Jaffray Jan 11 2016
Genomic Health Announces Preliminary 2015 Revenue and Confirms 2016 Growth Expectations Jan 08 2016
GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 08 2016
Genomic Health Announces Preliminary 2015 Revenue and Confirms 2016 Growth Expectations Jan 08 2016
Genomic Health Upgraded By Canaccord, $44 Per Share Target Predicted Jan 06 2016
Genomic Health to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
Genomic Health to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK